Oragenics, Inc. filed its 10-K on Apr 17, 2023 for the period ending Dec 31, 2022. In this report its auditor, Mayer Hoffman McCann P.C., gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.71 USD | +4.27% | -9.22% | -70.31% |
May. 16 | Sector Update: Health Care Stocks Ease Thursday Afternoon | MT |
May. 16 | Oragenics to Start Phase 2 Concussion Treatment Drug Trial -- Shares Rise | MT |
1st Jan change | Capi. | |
---|---|---|
-70.31% | 7.35M | |
+8.70% | 114B | |
+11.39% | 104B | |
-12.72% | 22.41B | |
-1.05% | 22.28B | |
-5.29% | 19.07B | |
-38.29% | 18B | |
-3.95% | 17.89B | |
+7.81% | 14.28B | |
+35.54% | 12.55B |
- Stock Market
- Equities
- OGEN Stock
- News Oragenics, Inc.
- Oragenics, Inc. Auditor Raises 'Going Concern' Doubt